Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/56506
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
SEROEPIDEMIOLOGY OF SARS-COV-2 ON A PARTIALLY VACCINATED ISLAND IN BRAZIL: DETERMINANTS OF INFECTION AND VACCINE RESPONSE
Author
Cerbino-Neto, José
Peres, Igor Tona
Varela, Margareth Catoia
Brandão, Luciana Gomes Pedro
Matos, Juliana Arruda de
Pinto, Luiz Felipe
Costa, Marcellus Dias da
Garcia, Márcio Henrique de Oliveira
Soranz, Daniel
Maia, Maria de Lourdes de Sousa
Krieger, Marco Aurélio
Cunha, Rivaldo Venâncio da
Camacho, Luiz Antonio Bastos
Ranzani, Otavio
Hamacher, Silvio
Bozza, Fernando A.
Penna, Gerson Oliveira
Peres, Igor Tona
Varela, Margareth Catoia
Brandão, Luciana Gomes Pedro
Matos, Juliana Arruda de
Pinto, Luiz Felipe
Costa, Marcellus Dias da
Garcia, Márcio Henrique de Oliveira
Soranz, Daniel
Maia, Maria de Lourdes de Sousa
Krieger, Marco Aurélio
Cunha, Rivaldo Venâncio da
Camacho, Luiz Antonio Bastos
Ranzani, Otavio
Hamacher, Silvio
Bozza, Fernando A.
Penna, Gerson Oliveira
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Rio de Janeiro City Government. Municipal Health Department of Rio de Janeiro. Rio de Janeiro, RJ, Brazil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Pontifical Catholic University of Rio de Janeiro. Department of Industrial Engineering and Tecgraf Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / National Institute of Traumatology and Orthopedics Jamil Haddad. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. School of Medicine. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Rio de Janeiro City Government. Municipal Health Department of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil / Rio de Janeiro City Government. Municipal Health Department of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Biomanguinhos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Presidência. Vice-Presidência de Produção e Inovação em Saúde. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Presidência. Coordenação de Vigilância Sanitária e Laboratórios de Referência. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Universitat Pompeu Fabra. CIBER Epidemiología y Salud Pública. Barcelona Institute for Global Health (ISGlobal). Barcelona, Spain / Universidade de São Paulo. Heart Institute. Hospital das Clínicas. Pulmonary Division. São Paulo, SP, Brazil.
Pontifical Catholic University of Rio de Janeiro. Department of Industrial Engineering and Tecgraf Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Fiocruz Brasília. Escola de Governo em Saúde. Brasília, DF, Brasil / University of Brasília. Tropical Medicine Centre. Brasília, DF, Brazil.
Pontifical Catholic University of Rio de Janeiro. Department of Industrial Engineering and Tecgraf Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / National Institute of Traumatology and Orthopedics Jamil Haddad. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. School of Medicine. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Rio de Janeiro City Government. Municipal Health Department of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil / Rio de Janeiro City Government. Municipal Health Department of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Biomanguinhos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Presidência. Vice-Presidência de Produção e Inovação em Saúde. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Presidência. Coordenação de Vigilância Sanitária e Laboratórios de Referência. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Universitat Pompeu Fabra. CIBER Epidemiología y Salud Pública. Barcelona Institute for Global Health (ISGlobal). Barcelona, Spain / Universidade de São Paulo. Heart Institute. Hospital das Clínicas. Pulmonary Division. São Paulo, SP, Brazil.
Pontifical Catholic University of Rio de Janeiro. Department of Industrial Engineering and Tecgraf Institute. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Fiocruz Brasília. Escola de Governo em Saúde. Brasília, DF, Brasil / University of Brasília. Tropical Medicine Centre. Brasília, DF, Brazil.
Abstract
Background: A vaccination campaign targeted adults in response to the pandemic in the City of Rio de Janeiro. Objective: We aimed to evaluate the seroprevalence of SARS-CoV-2 antibodies and identify factors associated with seropositivity on vaccinated and unvaccinated residents. Methods: We performed a seroepidemiologic survey in all residents of Paquetá Island, a neighborhood of Rio de Janeiro city, during the COVID-19 vaccine roll-out. Serological tests were performed from June 16 to June 19, 2021, and adjusted seropositivity rates were estimated by age and epidemiological variables. Logistic regression models were used to estimate adjusted ORs for risk factors to SARS-CoV-2 seropositivity in non-vaccinated individuals, and potential determinants of the magnitude of antibody responses in the seropositive population. Results: We included in the study 3,016 residents of Paquetá (83.5% of the island population). The crude seroprevalence of COVID-19 antibodies in our sample was 53.6% (95% CI = 51.0, 56.3). The risk factors for SARS-CoV-2 seropositivity in non-vaccinated individuals were history of confirmed previous COVID-19 infection (OR = 4.74; 95% CI = 3.3, 7.0), being a household contact of a case (OR = 1.93; 95% CI = 1.5, 2.6) and in-person learning (OR = 2.01; 95% CI = 1.4, 3.0). Potential determinants of the magnitude of antibody responses among the seropositive were hybrid immunity, the type of vaccine received, and time since the last vaccine dose. Being vaccinated with Pfizer or AstraZeneca (Beta = 2.2; 95% CI = 1.8, 2.6) determined higher antibody titers than those observed with CoronaVac (Beta = 1.2; 95% CI = 0.9, 1.5). Conclusions: Our study highlights the impact of vaccination on COVID-19 collective immunity even in a highly affected population, showing the difference in antibody titers achieved with different vaccines and how they wane with time, reinforcing how these factors should be considered when estimating effectiveness of a vaccination program at any given time. We also found that hybrid immunity was superior to both infection-induced and vaccine-induced immunity alone, and online learning protected students from COVID-19 exposure.
Share